Generics - Pricing

Filter

Current filters:

Pricing

Popular Filters

82 to 106 of 1772 results

Call for South African govt to ensure affordable medicines for all

03-03-2014

South Africa’s National Education, Health and Allied Workers' Union (NEHAWU) has reiterated its position,…

Patents & Trade marksPharmaceuticalPoliticsPricingRest of the WorldSouth Africa

Eli Lilly to expand manufacturing plants in Brazil’s growing pharma market

Eli Lilly to expand manufacturing plants in Brazil’s growing pharma market

03-03-2014

US pharma major Eli Lilly’s subsidiary in Brazil will invest 15 million real ($6.4 million) over the…

BrazilEli LillyPharmaceuticalPricingProductionSouth America

Natco prevails in Indian Copaxone patent dispute with Teva

Natco prevails in Indian Copaxone patent dispute with Teva

03-03-2014

Hyderabad, India-based Natco Pharma has won a significant patent battle against Israeli generics giant…

Asia-PacificCopaxoneGenericsIndiaNatco PharmaPatents & Trade marksTeva Pharmaceutical Industries

Sanofi Pasteur wins order for IPV from UNICEF, cutting price to $1 per dose

28-02-2014

Sanofi Pasteur, the vaccines division of French drug major Sanofi, says that UNICEF, the organization…

GlobalMarkets & MarketingPharmaceuticalPricingSanofiSanofi PasteurVaccines

Valeant Pharma returns to profit, boosted by B&L acquisition

27-02-2014

Canadian drugmaker Valeant Pharmaceuticals International has announces fourth quarter financial results…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Mylan 4th-qtr 2013 adjusted diluted EPS increases 20%, beating expectations

27-02-2014

US generics major Mylan reported financial results for the fourth-quarter and full year 2013, showing…

FinancialGenericsMylan Laboratories

Which place for orphan drugs in the strategy of pharma companies and payers?

27-02-2014

As the 7th Rare Disease Day will be held on February 28, ALCIMED, an innovation and new business consulting…

Markets & MarketingNovartisPharmaceuticalPricingRare diseasesResearchRocheSanofi

Negative NICE appraisal for Eli Lilly’s Alimta as maintenance therapy

27-02-2014

UK health care guidance body the National Institute for Health and Care Excellence (NICE) has published…

AlimtaEli LillyNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

BIO urges Indiana Governor to sign Bill on interchangeable biologic medicines

27-02-2014

US trade group the Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF)…

BiosimilarsGenericsLegalNorth AmericaRegulationUSA

Cell Thera’s NHL drug Pixuvri gets backing from UK’s NICE

27-02-2014

US biotech firm Cell Therapeutics has received positive news from the UK’s drugs watchdog for use of…

BiotechnologyCell TherapeuticsNorthern EuropeOncologyPixuvriPricingRegulationUK

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

26-02-2014

The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

UK’s NICE gives green light to Bayer’s Eylea in final guidance

26-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final guidance…

BayerEyleaNorthern EuropeOphthalmicsPharmaceuticalPricingRegulationUK

New pharma policy is "trial and error” at patients’ expense, says Germany’s VFA

26-02-2014

The German Bundestag (Parliament) is implementing a number of pharmaceutical policy changes within the…

GermanyNorthern EuropePharmaceuticalPoliticsPricing

NICE guidance will deprive UK patients with newly-diagnosed advanced melanoma of Yervoy

25-02-2014

US drug major Bristol-Myers Squibb today expressed its disappointment that the UK drugs watchdog the…

Bristol-Myers SquibbNorthern EuropeOncologyPharmaceuticalPricingRegulationUKYervoy

Ranbaxy temporarily suspends shipments from Toansa and Dewas plants

25-02-2014

Indian drugmaker Ranbaxy Laboratories has announced in a letter to the Stock Exchange that it has temporarily…

Asia-PacificDaiichi SankyoGenericsIndiaProductionRanbaxy Laboratories

FDA proposed rule to change label requirements would cause dangerous confusion, raise costs

24-02-2014

The Food and Drug Administration’s Proposed Rule to change prescription drug label requirements risks…

GenericsNorth AmericaRegulationUSA

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

IQWiG now finds “major” benefit for Xtandi

24-02-2014

In an early benefit assessment under Germany’s Act on the Reform of the Market for Medicinal Products…

Astellas PharmaGermanyMedivationNorthern EuropeOncologyPharmaceuticalPricingRegulationXtandi

MSF warns of impact of proposed EU trade mark infringement measures

24-02-2014

Ahead of a vote tomorrow in the European Parliament on proposed strengthened EU enforcement of European…

EuropeGenericsPatents & Trade marks

Indian drugmakers readying for next “Patent cliff”

24-02-2014

The strategic drug reviews, as well as mergers and acquisitions – such as Actavis buying out Forest…

Asia-PacificGenericsIndiaMergers & AcquisitionsPatentsPharmaceuticalRegulation

US GPhA member support for GDUFA promise and progress

US GPhA member support for GDUFA promise and progress

21-02-2014

The US Food and Drug Administration’ Office of Generic Drugs acting director Kathleen Uhl, highlighted…

GenericsNorth AmericaRegulationUSA

Setting the record straight: Australia’s PBS expenditure is in decline

21-02-2014

Comments made this week by Australia’s federal Health Minister, Peter Dutton MP, about expenditure…

Asia-PacificAustraliaFinancialGenericsHealthcarePharmaceutical

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

20-02-2014

Acquisitive Ireland-headquartered generics major Actavis says that net revenue leapt 59% to $2.779 billion…

ActavisFinancialGenerics

82 to 106 of 1772 results

Back to top